Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
- Conditions
- PertussisTetanusDiphtheria
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 647
- Registration Number
- NCT00319553
A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX
- Conditions
- Japanese Encephalitis
- Interventions
- Biological: ChimeriVax™-JE vaccineBiological: JE-VAX® vaccine
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT00319592
- Locations
- 🇺🇸
Clinical Pharamacology Center, Lenexa, Kansas, United States
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV
- Conditions
- PertussisDiphtheriaPoliomyelitisTetanus
- Interventions
- Biological: DTaP-IPV combined vaccineBiological: DTaP vaccine
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 442
- Registration Number
- NCT00319852
Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia
- Conditions
- Attention Deficit Hyperactivity Disorder
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2009-04-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 201
- Registration Number
- NCT00318448
- Locations
- 🇨🇦
Sanofi-Aventis Administrative Office, Laval, Canada
Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome
- Conditions
- Coronary Disease
- Interventions
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3241
- Registration Number
- NCT00317395
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria
- Conditions
- Malaria
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1032
- Registration Number
- NCT00316329
- Locations
- 🇨🇲
CHU, Yaounde, Cameroon
🇲🇬Centre de santé, Tsiroanomandidy, Madagascar
TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults
- Conditions
- TonsillitisPharyngitis
- First Posted Date
- 2006-04-18
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 233
- Registration Number
- NCT00315549
- Locations
- 🇨🇷
Sanofi-Aventis, San Jose, Costa Rica
TELI TON - Telithromycin in Tonsillitis
- Conditions
- TonsillitisPharyngitis
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 314
- Registration Number
- NCT00315042
- Locations
- 🇵🇦
Sanofi-Aventis, Panama, Panama
TELI COM - Telithromycin in Children With Otitis Media
- Conditions
- Otitis Media, SuppurativeOtitis Media, Purulent
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1500
- Registration Number
- NCT00315003
- Locations
- 🇵🇪
Sanofi-Aventis, Lima, Peru
Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
- Conditions
- EncephalitisJapanese Encephalitis
- Interventions
- Biological: 0.9% SalineBiological: ChimeriVax-JE, Japanese Encephalitis vaccine
- First Posted Date
- 2006-04-13
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2004
- Registration Number
- NCT00314132